The docking of 4 classes of anti-tumor β-carbolines and 3 classes of anti-thrombotic tetrahydro-β-carbolines from our sample library towards the active site of P-selectin led to the rational design, and THPDTPI was theoretically assigned a promising inhibitor of P-selectin. The gene discussed is SELP; the disease is neoplasm.